Skip to main content
Clinical Trials/NCT04127656
NCT04127656
Terminated
Not Applicable

Symptom Changes in Infants Fed an Amino Acid-based Formula

Abbott Nutrition3 sites in 1 country26 target enrollmentDecember 16, 2019
ConditionsFood Allergy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Food Allergy
Sponsor
Abbott Nutrition
Enrollment
26
Locations
3
Primary Endpoint
Food Allergy Symptom Improvement
Status
Terminated
Last Updated
4 years ago

Overview

Brief Summary

To observe the effects of an amino acid-based formula on symptoms associated with food allergies in infants.

Registry
clinicaltrials.gov
Start Date
December 16, 2019
End Date
December 16, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject is judged to be in good health as determined from subject's medical history
  • Subject is from a full-term birth with a gestational age of 37-42 weeks
  • Subject's birth weight was ≥ 2490 g (\~5 lbs. 8 oz.)
  • Subject has been documented to have CMPA and/or multiple food allergies, FPIES or gastrointestinal eosinophilic disorders.
  • Subject is experiencing persistent feeding intolerance symptoms including any of the following: regurgitation/vomiting associated with feeding (within 1 hour), constipation, diarrhoea, hematochezia (blood in the stool), crying, gassiness (wind), and/or skin rash/eczema.
  • Parent(s) confirm their intention to feed their infant study product during the study period.
  • Parent(s) confirm their intention not to administer vitamin or mineral supplements to their infant from enrolment through the duration of the study, unless instructed otherwise by their healthcare professional.
  • Infant using medications (OTC medications for gas \[wind\]), home remedies (such as juice for constipation), herbal preparations, prebiotics, probiotics or rehydration fluids that might affect Gl tolerance may not be enrolled unless the parent agrees to discontinue the use of these agents prior to enrolment or a healthcare professional recommends their continued use.
  • Subject's parent(s) has voluntarily signed and dated an ICF, approved by an IEC/IRB and provided applicable privacy regulation authorisation prior to any participation in the study.

Exclusion Criteria

  • Subject is receiving steroids or antibiotics
  • Subject is tube-fed
  • Subject has received an amino acid-based formula
  • Subject has been diagnosed with: Short bowel syndrome, Inflammatory bowel disease, Pancreatic disease, Protein maldigestion (malnutrition), Mast cell disorder
  • Subject is participating in another study that has not been approved as a concomitant study by AN

Outcomes

Primary Outcomes

Food Allergy Symptom Improvement

Time Frame: Baseline to Day 28

Parent Completed Symptom Diary

Secondary Outcomes

  • Time to Symptom Resolution or Reduction(Baseline to Day 28)
  • Study Formula Intake(Baseline to Day 28)
  • Change in Length(Baseline to Day 28)
  • Change in Weight(Baseline to Day 28)

Study Sites (3)

Loading locations...

Similar Trials